Skip to main content

Oregon State Flag An official website of the State of Oregon »

Oregon.gov Homepage

Drug reviews

SURVEY LINKS (Request for information about drugs under review) 2025 Oregon PDAB drug review resources

2025 Oregon PDAB drug review documents, videos, minutes

Drug review group Review documents Meeting video Meeting minutes
Vraylar, Entresto, Ajovy, Emgality, Nurtec, Ubrelvy
 July 16, 2025 July 16, 2025 July 16, 2025
Trelegy, Eliquis, Xarelto, Cosentyx, Creon Aug. 20, 2025 Aug. 20, 2025 Aug. 20, 2025
Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity Sept. 17, 2025 Sept. 17, 2025 Sept. 17, 2025
Insulin products: Basaglar KwikPen, Insulin Glardine-yfgn, Lantus, Lantus SolorStar, Semglee-yfgn, Toujeo Max SolarStar, Toujeo SoloStar
Oct. 15, 2025 Oct. 15, 2025 Oct. 15, 2025

Document links will be updated one week before board meetings Video links will be updated the day after board meetings Meeting minute links will be updated after board approval the following month

August 20, 2025 Board Meeting Resources

July 16, 2025 Board Meeting Resources

June 18, 2025 Board Meeting Resources

April 16, 2025 Board Meeting Resources

March 19, 2025 Board Meeting Resources

February 19, 2025 Board Meeting Resources

January 15, 2025 Board Meeting Resources


About Oregon PDAB drug reviews: The Prescription Drug Affordability Board conducts annual drug reviews for identified drugs and insulin products as directed by ORS 646A.694 using criteria established in Oregon law. In the drug reviews, the board narrows a list of prescription drugs to a subset list, reviews each drug and applies criteria to determine whether the drugs may cause affordability challenges for Oregonians and health care systems in the state. The board will submit a list of up to nine prescription drugs and at least one insulin product to the Oregon Legislature.

Data for the reviews comes from the Drug Price Transparency (DPT) program pursuant to ORS 646A.694, the Oregon Health Authority All Claims All Payers (APAC) data base, and information submitted by insurance carriers through a data call by Department of Consumer Business Services.

The board adopted two rules in 2023 to guide the board drug review process. OAR 925-200-0010 criteria for board selection of the subset list of drugs and OAR 925-200-0020 criteria for drug reviews.